Key terms
About VRCA
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VRCA news
Mar 01
7:28am ET
RBC Capital Remains a Buy on Verrica Pharmaceuticals (VRCA)
Mar 01
7:06am ET
Buy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansion
Mar 01
6:28am ET
Verrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Rating
Mar 01
6:22am ET
Verrica Pharmaceuticals price target raised to $13 from $12 at H.C. Wainwright
Feb 29
11:45am ET
Buy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptance
Feb 29
7:34am ET
Verrica Pharmaceuticals reports Q4 EPS (53c), consensus (53c)
Feb 12
3:06pm ET
Verrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options Traders
Feb 05
7:34am ET
Verrica Pharmaceuticals files lawsuit against Dormer Laboratories
Jan 05
7:30am ET
Verrica Pharmaceuticals announces last patient dosed in Phase 2 trial of VP-315
Jan 04
7:32am ET
Verrica Pharmaceuticals receives Type C meeting minutes on YCANTH development
Jan 03
7:32am ET
Verrica Pharmaceuticals announces specialty pharmacy agreement with Walgreens
Dec 21
6:23am ET
Insider Trading: Verrica Stock (NASDAQ:VRCA) Gained on $6.9M Insider Buy
Dec 15
6:02am ET
Torii Pharmaceutical reports ‘positive’ results from Phase 3 trial of TO-208
No recent press releases are available for VRCA
VRCA Financials
Key terms
Ad Feedback
VRCA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VRCA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range